Roche Holding AG (RHHBY.PK), Monday announced that the U.S. Food and Drug Administration has cleared its Elecsys pTau181 test, a blood-based Alzheimer's test indicated as an aid in the initial assessment for Alzheimer's and other causes of cognitive decline in the primary-care setting.
The minimally invasive test, developed in partnership with Eli Lilly and Company (LLY), would help clinicians with information to help patients in early stages of cognitive decline.
The test was evaluated in a multicenter, non-interventional clinical study, showing that it could rule out Alzheimer's pathology with a 97.9 percent negative predictive value.
Moving forward, Roche is advancing a comprehensive portfolio that has the potential to further shape diagnostic pathways and support earlier, more accurate detection of neurological diseases.
Currently, RHHBY is trading at $45.08, down 1.29 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.